Together since 2007

Transforming money management to make financial markets accessible to all

Acquired since 2021

Enabling the human right of mobility to all

Acquired since 2017

Introducing Zero Trust mechanisms for a truly sale environment

Acquired since 1994

Introduced cyber security to the mass business market

Together since 2010

Harnessing the power of artificial vision to transform the lives of visually impaired

Together since 2020

Digital Learning Platform designed to optimize student engagement and learning outcome

Together since 2019

AI-driven end-to-end Fix & Flip platform

Together since 2021

First drone delivery service focused in the US suburbs.

Acquired by DG 2007

Global provider of digital advertising solutions that optimize the use of media, creative and data for enhanced performance.

Together since 2010

Leading investment house in Israel, managing over 77 Billion Dollars for private, business and institutional clients

Together since 2016

Developing and commercializing novel endovascular treatments for stroke

Together since 2012

Developing percutaneous implantable technologies for patients with chronic heart failure


Funding to support further development of V-Wave’s Unidirectional Interatrial Shunt for the treatment of Heart Failure.

Posted January 20, 2016   3
V-Wave Ltd. announced that it has completed a Series B financing of $28M.  New investors included Johnson &
Johnson Innovation – JJDC Inc., TriVentures, Pura Vida Investments and BioStar Ventures. Also participating
in the round are existing investors, BRM Group, Pontifax and Edwards Lifesciences.

The funds will support clinical evaluation and development, addition of senior management and manufacturing scale-up of V-Wave’s proprietary minimally invasive device for use in patients with chronic symptomatic HF.
The shunt is implanted trans-venously and placed in the atrial septum where it remains. Within the shunt is
a porcine tissue valve to assure only left to right shunting of blood and to reduce the probability of
paradoxical embolus. The device regulates left atrial pressure (LAP) by shunting excess blood volume away
from the left ventricle – the heart’s main pumping chamber.  Elevated LAP is the direct cause of worsening
symptoms and hospitalization in over 90% of HF patients. The Shunt is intended to relieve symptoms, improve
quality of life, and to reduce the need for acute hospitalization due to worsening episodes of HF in
patients who become symptomatic at minimal levels of activity.  To date, more than thirty patients have been successfully treated.

HF is the end-stage of many forms of heart disease and takes a high toll in terms of premature death,
deteriorating health, recurrent hospitalizations and heavy costs to healthcare systems. Although mainstay
treatment with medications may be effective, each year there are more than one million hospitalizations with acutely worsening HF in the U.S. alone.  Direct costs of HF exceed $30 billion, most of which goes for in-
patient care. The number of patients with HF is expected to double during the next two decades as baby
boomers age and develop heart disease.

Dr. Neal Eigler, MD, CEO of V-Wave said, “With the backing of our new and prior investors, we can now
accelerate development and clinical evaluation of a new therapy applicable for a large segment of HF
patients who need additional treatment options.  Together with company President Erez Rozenfeld, we are
building a team with the potential to make V-Wave’s unidirectional shunt achieve the data and milestones
needed for regulatory approvals and commercialization in the U.S. and around the world. “

Dr. Frank Litvack, MD, V-Wave Chairman and Partner at Pura Vida Investments added, “The V-Wave product has
the potential to radically transform the treatment for advanced, ambulatory Heart Failure. Clinical results
to date, in more than 30 patients with follow-up averaging 11 months, are highly encouraging. We are
delighted to be part of an investor syndicate that includes both strategic and financial investors with such deep understanding of the cardiovascular space.”

About the financial investors:
TriVentures is a medtech and digital health focused venture capital fund based in Israel and Palo Alto with
extensive experience in the cardiovascular sector.

Launched in 2012, Pura Vida is a U.S based investment firm focused on both public and private investments
across all subsectors of healthcare.

BioStar Ventures is a US VC partnership focused on medical devices and connected health technologies in
cardiovascular and orthopedic medicine.

BRM Group and Pontifax are Israel based venture firms that have supported V-Wave in the prior A and A-1
investment rounds.